Acura Pharmaceuticals(OTC) ACUR

Acura Pharmaceuticals, Inc. is a drug delivery innovator focused on developing technologies that enhance medication safety. The company offers a range of products, including prescription narcotics and over-the-counter medications, while actively advancing additional opioid products.

Products and Services

• Oxaydo tablets for managing moderate-to-severe pain
• Nexafed line for cold, sinus, and allergy relief
• Six additional opioid products in various development stages

Growth Outlook

• Strategic partnerships with Egalet US, Inc. for global commercialization
• Advancements in opioid product development may capture market share
• Focus on enhancing medication safety aligns with industry trends

Financial Highlights

• Recent quarterly revenue of $36,000, showing potential for growth
• Trailing twelve months (TTM) gross profit margin at 94.24%
• Current ratio of 0.72 indicates liquidity challenges

Acura Pharmaceuticals operates in the healthcare sector, specifically within the drug manufacturing industry. The company is headquartered in Palatine, Illinois, and has been in operation since 1935. With a focus on innovative drug delivery systems, Acura aims to address the growing concerns surrounding medication safety and abuse potential. The product portfolio includes Oxaydo, a prescription medication designed to manage pain while minimizing the risk of misuse. Additionally, the Nexafed line serves as a popular choice for consumers seeking relief from cold and allergy symptoms. The growth outlook for Acura Pharmaceuticals appears promising, particularly with its strategic partnerships and ongoing product development. Collaborations with established companies enhance the potential for successful market entry and expansion. The company's commitment to innovation in opioid products aligns with the increasing demand for safer medication options, positioning Acura favorably within the industry. Financially, Acura has shown some resilience, with a recent quarterly revenue of $36,000, indicating a potential upward trend. The gross profit margin of 94.24% reflects the company's ability to maintain profitability despite challenges. However, the current ratio of 0.72 suggests that liquidity may be a concern, warranting attention as the company navigates its growth trajectory. Overall, Acura Pharmaceuticals presents an intriguing opportunity for investors interested in the evolving landscape of drug delivery and medication safety.